LOUISVILLE, CO, May 20, 2008 – GlobeImmune, Inc. announced today completion of the planned enrollment of 120 subjects in a Phase 2 clinical trial to evaluate the GI-5005 Tarmogen® for the treatment of patients with chronic hepatitis C infection. GI-5005 … Continue reading
GlobeImmune Announces Completion of Planned Enrollment for GI-5005-02 Phase 2 Trial
May 20, 2008